---
title: "Repligen CEO Olivier Loeillot disposes of 5,426 common shares worth $976,680"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296648667.md"
description: "Repligen CEO Olivier Loeillot sold 5,426 common shares on August 20 at $180 per share, totaling approximately $976,680. The sale followed the exercise of stock options for the same number of shares at $141.79. Consequently, his direct ownership in Repligen decreased to 54,246 common shares."
datetime: "2026-08-21T20:07:14.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296648667.md)
  - [en](https://longbridge.com/en/news/296648667.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296648667.md)
generator: "portal-rs"
---

# Repligen CEO Olivier Loeillot disposes of 5,426 common shares worth $976,680

-   Repligen CEO Olivier Loeillot sold 5,426 common shares on Aug. 20 at USD 180. \* The sale followed the exercise of stock options for 5,426 shares at USD 141.79. \* Direct ownership fell to 54,246 common shares. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Repligen Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-058417), on August 21, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [RGEN.US](https://longbridge.com/en/quote/RGEN.US.md)

## Related News & Research

- [B. Metzler seel. Sohn & Co. AG Takes $3.60 Million Position in Repligen Corporation $RGEN](https://longbridge.com/en/news/296675317.md)
- [The Bull Case For Repligen (RGEN) Could Change Following Raised Guidance On Q2 Outperformance - Learn Why](https://longbridge.com/en/news/296262992.md)
- [Repligen CFO Jason K. Garland disposes of 733 common shares worth $106,285](https://longbridge.com/en/news/291002662.md)
- [Repligen says BioLife deal targets Q4 close pending regulatory, shareholder approvals](https://longbridge.com/en/news/294739855.md)
- [Repligen Conference: CEO touts differentiated bioprocessing portfolio; CFO targets 30% EBITDA margin](https://longbridge.com/en/news/280034896.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**